EAPH will be announcing third Exclusive Women's Health Product JV Partnership with Major Pharmaceutical Company. VS-Sense will bring in millions of dollars in revenues.
Easton Pharmaceuticals Announces That Its Partner Windsor Pharmaceuticals Has Received Regulatory Approvals For Products VS-Sense and AL-Sense For Central America and The Caribbean
Easton Pharmaceuticals
September 12, 2017 9:00 am0 Comments
TORONTO, ON–(Sep 12, 2017) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) and its JV partner BMV Medica SA de CV announces that its distributor Windsor Pharmaceuticals SA has received regulatory approval for two of its exclusively licensed Women’s Health Care products for Central America and the Caribbean.
After filing the regulatory documents subsequent to a signed sub-licensing agreement with Panama-based Windsor Pharmaceuticals, Easton and BMV Medica have received confirmation that Windsor Pharmaceuticals has received government regulatory approval to begin the marketing and selling of products “VS-Sense” and “AL-Sense” initially in Guatemala, with the other territories, El Salvador, Honduras, Panama, Costa Rica, Nicaragua, and the Dominican Republic, to follow shortly thereafter.
The region possesses a total population of over 50,000,000 where Windsor Pharmaceuticals SA has projected sales in excess of $3,000,000 in the second full year of launch for both of its licensed products “AL-Sense” and “VS-Sense”. Thereafter, market penetration increases and other products will be added. Focus group research with gynecologists in the region have indicated a strong demand for both products which coincides with growing global sales of these products, supporting the belief in the region that a company such as Windsor Pharmaceuticals SA with innovative specialty products can fill the current void in product offerings to the Obstetricians/Gynecologists. Sales are expected to commence in Q4 now that the initial regulatory approval has been received. Orders for product have been placed with manufacturers slated for October delivery.
Products Overview:
VS-Sense (VagiSense): is the current brand name of the BV (Bacterial Vaginosis) patented diagnostic test, planned for launch in Mexico and other larger markets in Latin America, but may be renamed depending on the outcome of partner discussions with multi-national pharmaceutical companies, initiated in late 2015 and early 2016. VagiSense (VS-Sense) is the same product Bayer Pharmaceuticals had licensed and launched in late 2015 in Europe under its brand, Canestest. Prestige Distribution is currently selling in the US under its brand, Monistat, with multi-million dollars in sales and growing.
AL-Sense (AmnioTest): patented amniotic fluid leak test will be marketed in two presentations to capture maximum market, and is a unique Point-of-Care diagnostic panty liner for women in late-stage pregnancy able to distinguish between urine and amniotic fluid (breaking of water).
